Leukemia in infants — defined as leukemia diagnosed before age 1 — is rare, accounting for roughly 2–5% of all childhood leukemia cases. But what it lacks in frequency, it makes up for in severity. Infant leukemia is biologically distinct from the leukemia seen in older children, driven by unique genetic rearrangements (especially in the KMT2A gene, formerly called MLL) that make it more aggressive and harder to treat. Five-year survival rates hover around 50%, compared to over 90% for older children with ALL.
If you’re here because your infant has been diagnosed — or you’re a medical professional looking for a concise clinical overview — this article covers the known causes, how diagnosis works in practice, the symptoms that typically prompt evaluation, and the emerging treatments that are finally starting to shift outcomes.
What Causes Leukemia in Infants?
The honest answer: we don’t fully know. But we understand more than we did a decade ago.
The KMT2A (MLL) Gene Rearrangement
The single most important biological factor in infant leukemia is a rearrangement of the KMT2A gene on chromosome 11q23. This rearrangement is found in approximately 75–80% of infant ALL cases and about 50% of infant AML cases. KMT2A normally regulates gene expression during blood cell development. When it fuses with one of over 90 known partner genes, it produces a fusion protein that drives uncontrolled proliferation of immature blood cells.
What makes this particularly striking: these rearrangements are thought to occur in utero, often as a single catastrophic genetic event. Many infants with KMT2A-rearranged leukemia have very few additional mutations — the rearrangement alone is enough to trigger disease.
Environmental and Prenatal Factors
Several prenatal exposures have been investigated as potential contributors:
- Topoisomerase II inhibitors — Dietary flavonoids (found in certain fruits, vegetables, soy, and coffee) and some medications can inhibit topoisomerase II, an enzyme involved in DNA repair. Epidemiological studies suggest a possible link, though the data remains inconclusive.
- Maternal smoking — Associated with a modestly increased risk, likely through DNA-damaging metabolites crossing the placenta.
- Pesticide exposure — Some case-control studies have reported associations, particularly with residential pesticide use during pregnancy.
No single environmental factor has been definitively proven to cause infant leukemia. Most cases arise without any identifiable external trigger.
Signs and Symptoms: What Parents and Clinicians Notice First
Infant leukemia progresses fast. Symptoms often develop over days to weeks, not months. Because infants can’t verbalize how they feel, the clinical picture relies heavily on physical exam findings and parental observations.
| Symptom/Sign | Underlying Cause | How Common |
|---|---|---|
| Pallor, lethargy, poor feeding | Anemia (low red blood cells) | Very common |
| Petechiae, bruising, bleeding | Thrombocytopenia (low platelets) | Very common |
| Recurrent or persistent fevers | Neutropenia (low functional white cells) | Common |
| Hepatosplenomegaly (enlarged liver/spleen) | Leukemic organ infiltration | Very common (~70–80%) |
| Skin nodules (leukemia cutis) | Skin infiltration by leukemic cells | More common than in older children (~30%) |
| CNS symptoms (bulging fontanelle, irritability) | CNS leukemia involvement | ~10–20% at diagnosis |
Leukemia cutis — bluish or violaceous skin nodules — is a particularly characteristic finding in infant leukemia that is relatively uncommon in older pediatric patients. Its presence should prompt immediate hematologic evaluation.
How Infant Leukemia Is Diagnosed
Diagnosis follows a structured workup that moves quickly once leukemia is suspected:
- Complete blood count (CBC) with differential — Often shows markedly elevated white blood cell count (WBC >100,000/µL in ~50% of infant ALL cases), anemia, and thrombocytopenia.
- Peripheral blood smear — Reveals circulating blast cells.
- Bone marrow biopsy and aspirate — The definitive diagnostic test. Confirms leukemia when ≥20% blasts are present (WHO criteria) or ≥25% (COG criteria).
- Immunophenotyping (flow cytometry) — Classifies the leukemia subtype. Infant ALL is often pro-B ALL (CD10-negative), which carries a worse prognosis.
- Cytogenetics and FISH — Identifies KMT2A rearrangements and partner genes. The specific fusion partner (e.g., AF4, ENL, AF9) influences prognosis.
- Lumbar puncture — Evaluates CNS involvement at diagnosis.
Turnaround for the full diagnostic picture, including molecular studies, typically takes 5–10 days, though treatment often begins before all results are finalized.
Prognosis: What the Numbers Actually Look Like
| Subgroup | 5-Year Event-Free Survival |
|---|---|
| Infant ALL, KMT2A-rearranged | ~30–40% |
| Infant ALL, KMT2A-germline (no rearrangement) | ~75–85% |
| Infant AML | ~50–60% |
| Older children with ALL (for comparison) | ~90% |
The gap is stark. KMT2A status is the single strongest prognostic factor. Age at diagnosis also matters — infants diagnosed before 90 days of life tend to have worse outcomes than those diagnosed closer to their first birthday.
Emerging Treatments Changing the Landscape
Standard chemotherapy regimens (like Interfant-06) have produced modest improvements over the past two decades, but survival for KMT2A-rearranged infant ALL has plateaued. That’s driving a wave of targeted and immunotherapy-based approaches.
Menin Inhibitors
Revumenib (SNDX-5613) is the most exciting development in years. Menin is a scaffolding protein that KMT2A fusion proteins require to drive leukemia. Revumenib blocks this interaction. In early clinical trials (AUGMENT-101), it has shown complete remission rates of approximately 30% in heavily pretreated patients — remarkable for a single agent in refractory disease. It received FDA accelerated approval in late 2024 for relapsed/refractory KMT2A-rearranged acute leukemia, and pediatric trials are actively enrolling.
CAR-T Cell Therapy
CD19-directed CAR-T therapy (such as tisagenlecleucel) has transformed relapsed B-cell ALL in older children. Its application in infants is more complex due to the pro-B immunophenotype and manufacturing challenges with small patients, but case series have shown responses. Trials targeting other antigens are underway.
Bispecific Antibodies
Blinatumomab, a CD19/CD3 bispecific T-cell engager, has been incorporated into frontline infant ALL protocols (e.g., Interfant-21) as a post-induction consolidation strategy. Early data suggest it may help deepen remissions, particularly in achieving MRD-negative status.
Epigenetic Therapies
Because KMT2A rearrangements fundamentally dysregulate epigenetic programming, agents like DOT1L inhibitors, BET inhibitors, and histone deacetylase (HDAC) inhibitors are being studied in preclinical and early clinical settings.
When to Seek Immediate Medical Attention
Take your infant to a pediatrician or emergency department without delay if you notice:
- Unexplained bruising or petechiae (tiny red/purple dots on the skin)
- Persistent pallor, extreme fatigue, or refusal to feed
- A firm, distended abdomen (possible organ enlargement)
- Bluish skin nodules that appear out of nowhere
- Fever lasting more than a few days without clear cause
A simple CBC can raise or lower the suspicion for leukemia within hours. If abnormal, referral to a pediatric hematologist-oncologist should happen the same day.
Frequently Asked Questions
Is infant leukemia inherited?
In the vast majority of cases, no. The KMT2A rearrangements that drive most infant leukemia arise as spontaneous (somatic) events during fetal development, not from inherited mutations passed down by parents. Rare genetic syndromes (like Li-Fraumeni or Down syndrome) can increase leukemia risk, but these account for a small minority of cases.
Why is infant leukemia harder to treat than childhood leukemia?
Three main reasons: the KMT2A rearrangement creates a biologically distinct and aggressive disease; infant ALL cells are often CD10-negative pro-B cells that respond poorly to standard chemotherapy; and infants tolerate intensive chemotherapy less well than older children due to their developing organs and immature immune systems.
What is the survival rate for infant leukemia?
It depends heavily on subtype and KMT2A status. Infants with KMT2A-rearranged ALL have a 5-year event-free survival of approximately 30–40%. Infants with KMT2A-germline ALL fare much better, around 75–85%. Infant AML survival is roughly 50–60%. New targeted therapies like menin inhibitors may improve these numbers in coming years.
Can leukemia be detected before birth?
Leukemia itself is not part of routine prenatal screening, and it is almost never diagnosed prenatally. However, research has shown that KMT2A rearrangements can occur in utero, sometimes months before clinical symptoms appear after birth. There is currently no prenatal test offered for infant leukemia risk.
Are clinical trials available for infants with leukemia?
Yes. Major cooperative groups like the Children’s Oncology Group (COG) and the Interfant consortium run clinical trials specifically for infant leukemia. Newer trials are incorporating menin inhibitors, blinatumomab, and other targeted agents. Ask your child’s oncologist about eligibility, or search ClinicalTrials.gov for active studies.
